AtonRa Partners Reduces Stock Holdings in Inari Medical, Inc. (NASDAQ:NARI)

AtonRa Partners lowered its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 8.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,193 shares of the company’s stock after selling 384 shares during the quarter. AtonRa Partners’ holdings in Inari Medical were worth $272,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. Fifth Third Bancorp lifted its stake in Inari Medical by 54.3% in the third quarter. Fifth Third Bancorp now owns 486 shares of the company’s stock valued at $32,000 after buying an additional 171 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Inari Medical by 139.7% during the third quarter. Nisa Investment Advisors LLC now owns 1,189 shares of the company’s stock worth $78,000 after buying an additional 693 shares during the last quarter. Handelsinvest Investeringsforvaltning acquired a new position in Inari Medical in the 4th quarter valued at about $185,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Inari Medical during the 3rd quarter valued at approximately $204,000. Finally, Blair William & Co. IL acquired a new stake in Inari Medical during the 3rd quarter worth approximately $205,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

Inari Medical Trading Down 0.0 %

NARI traded down $0.01 during midday trading on Tuesday, hitting $37.94. The company’s stock had a trading volume of 311,241 shares, compared to its average volume of 1,128,051. The firm has a market cap of $2.20 billion, a P/E ratio of -1,265.00 and a beta of 0.84. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $71.85. The firm has a 50-day moving average price of $44.45 and a two-hundred day moving average price of $54.08.

Inari Medical (NASDAQ:NARI) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.09). Inari Medical had a negative net margin of 0.33% and a positive return on equity of 1.23%. The company had revenue of $132.10 million during the quarter, compared to analyst estimates of $131.82 million. During the same quarter last year, the business earned ($0.11) EPS. The firm’s revenue for the quarter was up 22.5% compared to the same quarter last year. On average, equities analysts expect that Inari Medical, Inc. will post -0.25 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on NARI shares. Truist Financial dropped their target price on Inari Medical from $61.00 to $52.00 and set a “hold” rating on the stock in a report on Friday, March 22nd. Needham & Company LLC restated a “buy” rating and set a $72.00 price objective on shares of Inari Medical in a research report on Wednesday, March 6th. Piper Sandler cut shares of Inari Medical from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $85.00 to $55.00 in a report on Thursday, February 29th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Inari Medical in a report on Friday, April 12th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $73.71.

Insider Activity at Inari Medical

In other news, Director William Hoffman sold 1,451 shares of the stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $40.00, for a total value of $58,040.00. Following the completion of the sale, the director now owns 999,782 shares of the company’s stock, valued at $39,991,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Inari Medical news, Director William Hoffman sold 1,451 shares of the stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $40.00, for a total transaction of $58,040.00. Following the transaction, the director now directly owns 999,782 shares in the company, valued at approximately $39,991,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Mitch C. Hill sold 6,000 shares of Inari Medical stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $40.96, for a total value of $245,760.00. Following the completion of the transaction, the chief financial officer now owns 181,294 shares of the company’s stock, valued at $7,425,802.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,451 shares of company stock worth $1,949,000. Company insiders own 10.60% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.